Zimbabwe has turned down a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of Washington's request for confidential biological samples.
The decision came to light after a official document from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesman later stated that the United States was seeking health data for research and profit while refused to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a deal acceptable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision comes after a similar case in Kenya, where a high court suspended a similar deal with the US after legal challenges were filed about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have so far signed similar health pacts, representing over $18.3bn in committed funds.
Details of the Declined Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be available to our people if a future disease outbreak arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral deals were disrupting systems already established via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This system is intended to guarantee that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued dialogue with our US partners on how subsequent co-operation could be structured in a manner that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but suggested that talks need to persist considering much of the country's HIV programmes relied on external financing.
"Where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
The halted deal underscores the continuing challenges between receiving vital foreign assistance and protecting a country's data in an increasingly data-driven world.